Skip to main content
Sophie  Papa

Dr Sophie Papa

Clinical Reader

Research interests

  • Cancer
  • Immunology

Contact details

Biography

Sophie Papa is a Clinical Reader in Immuno-oncology and Consultant Medical Oncologist at King’s College London and Guy’s and St Thomas’ NHS Foundation Trust (GSTT). Sophie undertook her medical training at the University of Oxford and Imperial College London. She completed a PhD in solid tumour CAR T-cell cancer immunotherapy from King’s College London in 2011.

She is a clinical academic with research interests in the field of immune-oncology. Her group have two areas of study: Firstly, strategies to enhance CAR T-cell clinical translation and secondly, cohort based investigation of mechanism of checkpoint inhibitor driven inflammatory disease. Sophie is a medical oncologist with a practice in malignant melanoma and Merkle cell carcinoma. As a principal investigator in the GSTT Early Phase Trials Team Sophie has expertise in the design and delivery of first in man studies. She has a particular focus on building skills and capabilities to deliver immune effector cell therapies for solid tumours. She is the lead for skin cancer research and chairs the biological safety committee.

The publication feed is not currently available.

Research

experimental-oncology
Experimental Oncology

The Experimental Oncology Programme is focused on the development of new treatments for solid tumours.

Project status: Ongoing

Immunology and Immunotherapy Programme Header
Cancer Immunology & Immunotherapy

Cancer Immunology represents a broad field of research that studies host-tumour interactions as therapeutic targets in the treatment of cancer.

Project status: Ongoing

News

Trial to repurpose cancer drug for patients with COVID-19 launches

A new trial repurposing a blood cancer drug for patients with COVID-19 is being launched.

covid cancer drug

Study identifies medications safe to use in COVID-19 treatment

A recent study has found that there is no evidence for or against the use of non-steroidal anti-inflammatory drugs such as ibuprofen for patients with COVID-19.

coronavirus ibuprofen

Sophie Papa recognised as life science trailblazer

Dr Sophie Papa was recently featured as one of the trailblazers and trendsetters shaping the future of the UK life science sector by BioBeat in their sixth...

Dr Sophie Papa

The publication feed is not currently available.

Research

experimental-oncology
Experimental Oncology

The Experimental Oncology Programme is focused on the development of new treatments for solid tumours.

Project status: Ongoing

Immunology and Immunotherapy Programme Header
Cancer Immunology & Immunotherapy

Cancer Immunology represents a broad field of research that studies host-tumour interactions as therapeutic targets in the treatment of cancer.

Project status: Ongoing

News

Trial to repurpose cancer drug for patients with COVID-19 launches

A new trial repurposing a blood cancer drug for patients with COVID-19 is being launched.

covid cancer drug

Study identifies medications safe to use in COVID-19 treatment

A recent study has found that there is no evidence for or against the use of non-steroidal anti-inflammatory drugs such as ibuprofen for patients with COVID-19.

coronavirus ibuprofen

Sophie Papa recognised as life science trailblazer

Dr Sophie Papa was recently featured as one of the trailblazers and trendsetters shaping the future of the UK life science sector by BioBeat in their sixth...

Dr Sophie Papa